Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$198.05 USD

198.05
4,101,681

-0.81 (-0.41%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $198.10 +0.05 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

Zacks Equity Research

Should Value Investors Consider AbbVie (ABBV) Stock Now?

by Zacks Equity Research

Let's see if AbbVie Inc. (ABBV) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Kinjel Shah headshot

Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients

by Kinjel Shah

Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.

Zacks Equity Research

Why AbbVie (ABBV) is a Great Dividend Stock Right Now

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Zacks Equity Research

Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up

by Zacks Equity Research

Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.

Kalyan Nandy headshot

Top Research Reports: Chevron, AbbVie, Phillips 66 & More

by Kalyan Nandy

Today's Research Daily features updated research reports on 16 major stocks, including Chevron (CVX), AbbVie (ABBV) and Phillips 66 (PSX).

Zacks Equity Research

Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Momenta (MNTA) reports a wider loss and misses on sales in Q2 .

Zacks Equity Research

ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat

by Zacks Equity Research

ImmunoGen (IMGN) reports narrower-than-expected loss in the second quarter and beats revenue estimates. The company provides updated guidance for 2019.

Kinjel Shah headshot

Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger

by Kinjel Shah

AbbVie (ABBV), Merck (MRK), Pfizer (PFE), Lilly (LLY) report Q2 results. Pfizer announces plan to merge off-patent unit, Upjohn with Mylan to form new company.

Zacks Equity Research

Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y

by Zacks Equity Research

Dr. Reddy's (RDY) earnings and sales increase year over year in the first quarter of fiscal 2020.

Zacks Equity Research

Bayer (BAYRY) Q2 Earnings Match Estimates, Sales Up Y/Y

by Zacks Equity Research

Bayer (BAYRY) reports in-line earnings in the second quarter of 2019.

Zacks Equity Research

AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises EPS View

by Zacks Equity Research

AbbVie (ABBV) beats second-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.

Zacks Equity Research

Bristol-Myers Squibb (BMY) Catches Eye: Stock Jumps 5%

by Zacks Equity Research

Bristol-Myers Squibb (BMY) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Zacks Equity Research

AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

AbbVie (ABBV) delivered earnings and revenue surprises of 2.26% and 1.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AstraZeneca (AZN) Jumps: Stock Rises 5.7%

by Zacks Equity Research

AstraZeneca (AZN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Zacks Equity Research

AbbVie (ABBV) Beats Q2 Earnings and Revenues, Shares Up

by Zacks Equity Research

AbbVie's (ABBV) second-quarter 2019 earnings and revenues both beat estimates. The company raised its guidance for adjusted earnings in 2019.

Christopher Vargas headshot

Buy Merck & Co (MRK) Stock Ahead of Q2 Earnings Report?

by Christopher Vargas

Merck & Co (MRK) is set to report its fiscal 2019 second quarter earnings before the opening bell on July 30th.

Zacks Equity Research

Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

by Zacks Equity Research

Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas

Zacks Equity Research

Should You Buy AbbVie (ABBV) Ahead of Earnings?

by Zacks Equity Research

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised

by Zacks Equity Research

Roche's (RHHBY) performance in the first half of 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

Mitchell Moore headshot

What to Expect from Sanofi's (SNY) Q2 Earnings (Revised)

by Mitchell Moore

Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?

Mitchell Moore headshot

What to Expect from Sanofi's (SNY) Q2 Earnings

by Mitchell Moore

Sanofi (SNY) stock is down 1.8% in 2019 and has been volatile most of the year. Will this slight cumulative downtrend turn around after SNY reports Q2 earnings?

Zacks Equity Research

Merck (MRK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive second-quarter sales. However, genericization of key drugs and increased competition are concerns.

Zacks Equity Research

Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Zacks Equity Research

Eli Lilly (LLY) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead to an earnings beat for the company in Q2.

Sanghamitra Saha headshot

Use Rising P/E Strategy to Buy 5 Winning Stocks

by Sanghamitra Saha

Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.